FrancophonIA/ELRC3.0 huggingface dataset:
English: Approximately 25 µg
Estonian: ligikaudu 25 µg
English: Content (concentration)
Estonian: Pakendi sisu (konsentratsioon)
English: 50 (5 X 10) vials + 50 (5 X 10) pre-filled syringes without needles (multipack)
Estonian: 50 ( 5 x 10) viaali + 50 (5 x 10) eeltäidetud süstalt ilma nõelteta (multipakend)
English: Recombinant hepatitis B surface antigen (S protein), adsorbed
Estonian: Rekombinantne hepatiit B pinnaantigeen (S proteiin), adsorbeeritud
English: _ _1 After reconstitution, 1 dose (0.5 ml) contains: Diphtheria toxoid, adsorbed
Estonian: _ _1 Pärast lahustamist, 1 annus (0,5 ml) sisaldab: Difteeriatoksoid, adsorbeeritud
English: and tetanus toxoid (T), adsorbed (PRP-T)
Estonian: ja teetanusetoksoid (T), adsorbeeritud (PRP-T)
English: Conjugate of Haemophilus influenzae type b capsular polysaccharide (PRP)
Estonian: Konjugeeritud Haemophilus influenzae tüüp b kapsli polüsahhariid (PRP)
English: Pertactin, adsorbed
Estonian: Pertaktiin, adsorbeeritud
English: 10 vials + 10 pre-filled syringes + 20 needles
Estonian: 10 viaali + 10 eeltäidetud süstalt + 20 nõela
English: Filamentous haemagglutinin, adsorbed
Estonian: Filamentoosne hemaglutiniin, adsorbeeritud
English: 1 vial + 1 prefilled syringe + 2 needles
Estonian: 1 viaal + 1 eeltäidetud süstal + 2 nõela
English: 10 vials + 10 prefilled syringes without needles
Estonian: 10 viaali + 10 eeltäidetud süstalt ilma nõelteta
English: 1 vial + 1 prefilled syringe without needle
Estonian: 1 viaal + 1 eeltäidetud süstal ilma nõelata
English: MA (EU) number (Invented)n ame
Estonian: Müügiloa nr (Euroopa Liidus)
English: Pertussis toxoid, adsorbed
Estonian: Teetanusetoksoid, adsorbeeritud
English: Moreover, the intended use does not require medical supervision.
Estonian: Peale selle ei nõua ettenähtud kasutamine meditsiinilist järelevalvet.
English: Patients with open wounds, skin problems, high fever, severe infections and severe heart and circulation problems should not have full baths with lavender oil.
Estonian: Lahtiste haavade, nahaprobleemide, kõrge palaviku, raskete infektsioonide ning raske südame- ja vereringeprobleemidega patsiendid ei tohi võtta täisvanni, kuhu on lisatud lavendliõli.
English: The plant is cultivated or gathered to obtain the oil for medicinal use.
Estonian: Taime kasvatatakse või korjatakse, et saada meditsiiniliseks kasutamiseks õli.
English: Lavender oil EMA/HMPC/530968/2012
Estonian: Lavendliõli EMA/HMPC/530968/2012
English: What is lavender oil?
Estonian: Mis on lavendliõli?
English: Lavender oil medicines should only be used in adults and children over the age of 12 years.
Estonian: Lavendliõli sisaldavaid ravimeid võib kasutada ainult täiskasvanutel või üle 12-aastastel lastel.
English: Lavender oil
Estonian: Lavendliõli
English: Only few and mild side effects had been reported in studies with lavender oil, including very rare cases of allergic reactions.
Estonian: Lavendliõli kohta tehtud uuringutes oli teateid vaid vähestest ja kergetest kõrvaltoimetest, sealhulgas väga harvadest allergiliste reaktsioonide juhtudest.
English: Other information about lavender oil medicines
Estonian: Muu teave lavendliõli sisaldava ravimi kohta
English: At the time of the HMPC assessment, there were no major concerns over the safety of lavender oil.
Estonian: Taimsete ravimite komitee hinnanguraporti koostamise ajal ei esinenud lavendliõli ohutuse suhtes olulisi probleeme.
English: Further information on the risks associated with lavender oil medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave lavendliõli sisaldava ravimiga kaasnevate riskide, sh ettevaatusabinõude kohta selle ohutuks kasutamiseks, on kirjas taime monograafias Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: The HMPC concluded that, on the basis of its long-standing use, lavender oil can be used for the relief of mild symptoms of mental stress and exhaustion, and to aid sleep.
Estonian: Taimsete ravimite komitee järeldas, et pikaajalise kogemuse alusel võib lavendliõli kasutada vaimse stressi kergete sümptomite ja kurnatuse leevendamiseks ning une soodustamiseks .
English: EMA/HMPC/530968/2012
Estonian: EMA/HMPC/530968/2012 Taimsete ravimite komitee (HMPC)
English: Further information on the HMPC assessment of lavender oil, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave lavendliõli sisaldava ravimi hinnangu kohta, sh komitee kokkuvõtte detailne kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: For detailed information on the data assessed by the HMPC, see the HMPC assessment report.
Estonian: Üksikasjalikku teavet taimsete ravimite komitee poolt hinnatud uuringute kohta vaadake komitee hinnanguraportist .
English: What evidence supports the use of lavender oil medicines?
Estonian: Millised tõendid toetavad lavendliõli sisaldava ravimi kasutamist?
English: Any applications for the licensing of medicines containing lavender oil have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Estonian: Lavendliõli sisaldava ravimi müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimse ravimi müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslike järelduste kokkuvõtet.
English: Herbal medicines containing lavender oil are usually available in liquid forms to be taken by mouth or as a bath additive.
Estonian: Lavendliõli sisaldavaid taimseid ravimeid turustatakse tavaliselt vedelikena suukaudseks manustamiseks või kasutamiseks vannivee lisandina.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of lavender oil.
Estonian: See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb lavendliõli meditsiinilisi kasutusviise.
English: Detailed instruction on how to take lavender oil medicines and who can use them can be found in the package leaflet that comes with the medicine.
Estonian: Täpsed juhised, kuidas lavendliõli sisaldavaid ravimeid manustada ja kellele need on ette nähtud, on kirjas ravimi pakendi infolehes.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing lavender oil.
Estonian: ELi liikmesriigid võtavad taimsete ravimite komitee järeldusi arvesse, kui nad hindavad lavendliõli sisaldavate taimsete ravimite müügilubade taotlusi.
English: Lavender oil is obtained by a current of steam through the flowering tops of the plant.
Estonian: Lavendliõli toodetakse aurujoa juhtimisel läbi taime õitsvate ülaosade.
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Estonian: See tähendab, et kuigi kliiniliste uuringute andmeid on ebapiisavalt, on nende taimsete ravimite efektiivsus tõenäoline ja on tõendeid, et neid on sel viisil
English: What are the risks associated with lavender oil medicines?
Estonian: Mis riskid kaasnevad lavendliõli sisaldava ravimiga?
English: How are lavender oil medicines approved in the EU?
Estonian: Kuidas antakse Euroopa Liidus lavendliõli sisaldavale ravimile müügiluba?
English: Lavender oil is the common name for the essential oil of the plant Lavandula angustifolia Mill.
Estonian: Lavendliõli on taime Lavandula angustifolia Mill.
English: The HMPC conclusions on the use of medicines containing lavender oil are based on their ‘traditional use'.
Estonian: Taimsete ravimite komitee järeldused lavendliõli sisaldavate ravimite kasutamise kohta põhinevad nende traditsioonilisel kasutamisel.
English: This summary is not intended to provide practical advice on how to use medicines containing lavender oil.
Estonian: Kokkuvõttes ei anta lavendliõli sisaldava ravimi kasutamise kohta praktilisi nõuandeid.
English: For more information about treatment with lavender oil, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Estonian: Kui vajate lisateavet lavendliõli sisaldava ravimi kasutamise kohta, lugege palun pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For practical information about using lavender oil medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Estonian: Kui vajate lavendliõli sisaldava ravimi kasutamise kohta praktilisi nõuandeid, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Information on the use and licensing of lavender oil medicines in EU Member States should be obtained from the relevant national authorities.
Estonian: ELi liikmesriikides saab teavet lavendliõli sisaldava ravimi kasutamise ja müügiloa kohta riiklikult ravimiametilt.
English: Although lavender oil showed a possible effect on anxiety, stress and insomnia, the number of patients per study was too low to establish an effect.
Estonian: Taimsete ravimite komitee käsitles oma hinnanguraportis ka lavendliõli uuringuid erinevate seisunditega patsientidel, sealhulgas ärevuse ja unehäiretega patsientidel Kuigi lavendliõli näitas võimalikku toimet ärevusele, stressile ja unetusele, oli uuringus osalenud patsientide arv toime kindlakstegemiseks liiga väike.
English: Therefore, the HMPC conclusions on the use of lavender oil medicines are based on their long-standing use.
Estonian: Seetõttu põhinevad taimsete ravimite komitee järeldused lavendliõli sisaldavate ravimite kasutamise kohta nende pikaajalisel kasutamisel.
English: Further information on Vitrakvi can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/vitrakvi.
Estonian: Lisateave Vitrakvi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/vitrakvi.
English: In addition, the tumours shrank quickly (within 2 months).
Estonian: Lisaks sellele vähenesid kasvajad kiiresti (2 kuu jooksul).
English: The European Medicines Agency therefore concluded that its benefits are greater than its risks and that it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet järeldas seega, et Vitrakvi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: What measures are being taken to ensure the safe and effective use of Vitrakvi?
Estonian: Mis meetmed võetakse, et tagada Vitrakvi ohutu ja efektiivne kasutamine?
English: Vitrakvi (larotrectinib)
Estonian: Vitrakvi (larotrektiniib)
English: Adult patients should take 100 mg twice a day for as long as the cancer is stable and the side effects are acceptable.
Estonian: Täiskasvanud patsiendid peavad võtma 100 mg annuse kaks korda ööpäevas seni, kuni vähk püsib stabiilsena ja kõrvalnähud on talutavad.
English: Other information about Vitrakvi
Estonian: Muu teave Vitrakvi kohta
English: What is Vitrakvi and what is it used for?
Estonian: Mis on Vitrakvi ja milleks seda kasutatakse?
English: This data will come from the three ongoing studies which aim to confirm the benefits and safety of Vitrakvi and its longer term effect in children.
Estonian: Need andmed pärinevad kolmest toimuvast uuringust, mille eesmärk on kinnitada Vitrakvi kasulikkust ja ohutust ning selle pikaajalist toimet lastel.
English: Vitrakvi is available as a liquid (20 mg per ml) and capsules (25 and 100 mg) and is taken by mouth.
Estonian: Vitrakvit turustatakse vedelikuna (20 mg/ml) ja kapslitena (25 mg ja 100 mg) ning seda võetakse suu kaudu.
English: Vitrakvi (larotrectinib) EMA/457887/2019
Estonian: Vitrakvi (larotrektiniib) EMA/457887/2019
English: Why is Vitrakvi authorised in the EU?
Estonian: Miks Vitrakvi ELis heaks kiideti?
English: The most common side effects with Vitrakvi (which may affect more than 1 in 5 people) are tiredness, dizziness, constipation, nausea, vomiting, anaemia (low red blood cell counts) and high blood levels of alanine aminotransferase and aspartate aminotransferase (a sign of liver problems).
Estonian: Vitrakvi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on väsimus, peapööritus, kõhukinnisus, iiveldus, oksendamine, aneemia (erütrotsüütide ehk vere punaliblede vähesus) ning alaniinaminotransferaasi ja aspartaadi aminotransferaasi suur sisaldus veres (mis viitab maksaprobleemidele).
English: As for all medicines, data on the use of Vitrakvi are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Vitrakvi kasutamise kohta pidevat järelevalvet.
English: Most side effects are mild to moderate.
Estonian: Enamik kõrvalnähte on kerged või mõõdukad.
English: Although studies are still underway, the results released so far show that it is effective at reducing the size of patients' tumours.
Estonian: Kuigi uuringud alles toimuvad, tõendavad seni avaldatud tulemused, et ravim on patsientide kasvajate suuruse vähendamisel efektiivne.
English: For more information about using Vitrakvi, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Vitrakvi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Side effects reported with Vitrakvi are carefully evaluated and any necessary action taken to protect patients.
Estonian: Vitrakvi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vitrakvi have been included in the summary of product characteristics and the package leaflet.
Estonian: Vitrakvi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The dose for children is based on their body surface area (weight and height).
Estonian: Laste annus põhineb kehapindalal (arvutatakse kehamassi ja pikkuse järgi).
English: In these studies, 67% of patients who took Vitrakvi had a reduction in the size of their tumours, and the tumours on average shrank to less than half their original size.
Estonian: Nendes uuringutes oli Vitrakvit võtnute seas patsiente, kelle kasvaja suurus vähenes, 67% ja keskmiselt vähenes kasvaja suurus vähem kui pooleni algsest suurusest.
English: What information is still awaited for Vitrakvi?
Estonian: Mis teavet Vitrakvi kohta veel oodatakse?
English: Vitrakvi is used in patients whose tumours are advanced, have spread to other parts of the body or are not amenable to surgery, and who have no satisfactory alternative treatments.
Estonian: Vitrakvit kasutatakse patsientidel, kelle kasvaja on kaugele arenenud, siiretega (levinud organismis ka mujale) või mida ei saa eemaldada kirurgiliselt ning kellel puuduvad muud rahuldavad ravivõimalused.
English: Three ongoing studies in 102 patients with solid tumours with NTRK gene fusion showed that Vitrakvi is effective at reducing the size of patients' tumours.
Estonian: Kolmes praegu jätkuvas uuringus, milles osaleb NTRK-geeni fusiooniga 102 patsienti, on selgunud, et Vitrakvi on patsientide kasvajate suuruse vähendamisel efektiivne.
English: This means that there is more evidence to come about the medicine, which the company is required to provide.
Estonian: See tähendab, et ettevõte peab esitama ravimi kohta veel andmeid.
English: Since Vitrakvi has been given conditional authorisation, the company that markets Vitrakvi will provide further data on its effects.
Estonian: Et Vitrakvi on saanud müügiloa tingimusliku heakskiidu alusel, esitab Vitrakvi turustaja ravimi toime kohta täiendavaid andmeid.
English: What are the risks associated with Vitrakvi?
Estonian: Mis riskid Vitrakviga kaasnevad?
English: How is Vitrakvi used?
Estonian: Kuidas Vitrakvit kasutatakse?
English: NTRK gene fusion is a rare genetic abnormality that can occur in tumours from different parts of the body such as the lungs, thyroid glands and intestines.
Estonian: NTRK-geeni fusioon on haruldane geneetiline häire, mis võib esineda organismi eri osade (nt kopsude, kilpnäärme ja soole) kasvajates.
English: The active substance in Vitrakvi, larotrectinib, blocks the action of this protein, preventing the excessive growth of cancer cells and thereby slowing down the worsening of the cancer.
Estonian: Vitrakvi toimeaine larotrektiniib blokeerib selle valgu toime, takistades vähirakkude vohamist ja seega aeglustades haiguse süvenemist.
English: Vitrakvi is a cancer medicine for treating solid tumours with NTRK gene fusion.
Estonian: Vitrakvi on vähiravim, millega ravitakse NTRK-geeni fusiooniga soliidtuumoreid.
English: It contains the active substance larotrectinib.
Estonian: Ravim sisaldab toimeainena larotrektiniibi.
English: Vitrakvi differs from many other cancer medicines by targeting certain tumours with a specific gene arrangement wherever they occur in the body.
Estonian: Vitrakvi erineb paljudest muudest vähiravimitest, sest selle toime on suunatud spetsiifilise geenihäirega kasvajatele, olenemata kasvaja esinemiskohast organismis.
English: An overview of Vitrakvi and why it is authorised in the EU
Estonian: Ülevaade ravimist Vitrakvi ja ELis müügiloa väljastamise põhjendus
English: How does Vitrakvi work?
Estonian: Kuidas Vitrakvi toimib?
English: As for its safety, the side effects of Vitrakvi appear manageable.
Estonian: Ohutuse seisukohast peetakse Vitrakvi kõrvalnähte hallatavateks.
English: Vitrakvi has been given ‘conditional authorisation'.
Estonian: Vitrakvi on saanud müügiloa tingimusliku heakskiidu alusel.
English: In addition, the short time taken to shrink the tumours is important in relieving patients' symptoms.
Estonian: Lisaks on patsientide sümptomite leevendamisel oluline, et kasvajate suurus väheneb kiiresti.
English: Tumours with NTRK gene fusion produce an abnormal protein (TRK fusion protein), which causes the uncontrolled growth of cancer cells.
Estonian: NTRK-geeni fusiooniga kasvajad tekitavad ebanormaalset valku (TRK-fusioonvalku), mis põhjustab vähirakkude vohamist.
English: Vitrakvi should be started by a doctor experienced in using cancer medicines and can only be obtained with a prescription.
Estonian: Vitrakvi-ravi peab alustama ja jälgima vähiravis kogenud arst.
English: What benefits of Vitrakvi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vitrakvi kasulikkus?
English: The patients were followed up for an average of four and a half years.
Estonian: Patsiente jälgiti keskmiselt neli ja pool aastat.
English: This summary was last updated in 08-2015.
Estonian: Kokkuvõtte viimane uuendus: 08-2015.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Micardis on 16 December 1998.
Estonian: Euroopa Komisjon andis Micardise müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. detsembril 1998.
English: Other information about Micardis
Estonian: Muu teave Micardise kohta
English: A risk management plan has been developed to ensure that Micardis is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Micardise võimalikult ohutu kasutamine.
English: It is available as tablets (20, 40 and 80 mg).
Estonian: Seda turustatakse tablettidena (20 mg, 40 mg ja 80 mg).
English: The full EPAR for Micardis is available on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Micardise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Micardis?
Estonian: Mis meetmed võetakse, et tagada Micardise ohutu ja efektiivne kasutamine?
English: However, the following side effects are seen in between 1 and 10 patients in 1,000: upper respiratory tract infection (colds) including inflammation of the throat and sinuses, urinary tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red blood cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment (reduced kidney function) including sudden kidney failure, chest pain, asthenia (weakness) and increased blood levels of creatinine (a marker of muscle breakdown).
Estonian: 1-10 patsiendil 1000st on siiski esinenud järgmised kõrvalnähud: ülemiste hingamisteede nakkus (külmetus), sh kõri- ja ninakõrvalurgete põletik, kuseteede infektsioon, sh põieinfektsioon, aneemia (vere punaliblede vähesus), hüperkaleemia (vere liigne kaaliumisisaldus), depressioon, unetus, sünkoop (minestus), vertiigo (peapööritus), bradükardia (südameaeglus), hüpotensioon (madal vererõhk), düspnoe (raskendatud hingamine), köha, kõhuvalu, kõhulahtisus, düspepsia (kõrvetised), kõhupuhitus, oksendamine, hüperhidroos (liighigistamine), kihelus, lööve, müalgia (lihasevalu), seljavalu, lihasekrambid, neerupuudulikkus, sh äkiline neerupuudulikkus, rindkerevalu, asteenia (nõrkus) ja kreatiniini (lihaskoe lagunemise marker) suurenenud sisaldus veres.
English: Telmisartan
Estonian: Micardis telmisartaan
English: The combination of the two medicines was no more effective than either medicine taken alone and was linked to an increased risk of side effects.
Estonian: Kahe ravimi kombinatsioon ei olnud efektiivsem kui kumbki ravim eraldi ja kõrvalnähtude risk oli suurem.
English: This is a summary of the European public assessment report (EPAR) for Micardis.
Estonian: See on ravimi Micardis Euroopa avaliku hindamisaruande kokkuvõte.
English: Micardis is a medicine that contains the active substance telmisartan.
Estonian: Micardis on ravim, mis sisaldab toimeainena telmisartaani.
English: By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen.
Estonian: Blokeerides retseptorid, millega angiotensiin II tavaliselt seondub, peatab telmisartaan hormooni toime ja soodustab veresoonte laienemist.
English: It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.
Estonian: Samuti võimaldab ravim südamel lihtsamini verd pumbata, mis aitab vähendada kardiovaskulaarhäirete tekke riski.
English: The CHMP decided that Micardis's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Micardise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: What is Micardis?
Estonian: Mis on Micardis?
English: It is used in patients who have had problems due to blood clots in the past (such as heart disease, a stroke or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).
Estonian: Ravimit kasutatakse patsientidel, kellel on olnud trombootilisi tüsistusi (näiteks südamehaigus, infarkt või arterite haigus) või kellel on II tüüpi diabeet (suhkurtõbi), mis on kahjustanud elundeid (näiteks silmi, südant või neere).
English: If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Estonian: Kui see ei alanda vererõhku soovitud tasemeni, võib annust suurendada 80 mg-ni või täiendada ravi muu kõrgvererõhuravimiga, näiteks hüdroklorotiasiidiga.